Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice Derivation and Validation of a Risk Model From the EVENT Registry

被引:73
作者
Stolker, Joshua M. [1 ]
Kennedy, Kevin F. [1 ]
Lindsey, Jason B. [1 ]
Marso, Steven P. [1 ]
Pencina, Michael J. [3 ]
Cutlip, Donald E. [3 ]
Mauri, Laura [3 ]
Kleiman, Neal S. [2 ]
Cohen, David J. [1 ]
机构
[1] St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA
[2] Methodist DeBakey Heart Ctr, Houston, TX USA
[3] Harvard Clin Res Inst, Boston, MA USA
关键词
restenosis; drug-eluting stents; percutaneous coronary intervention; risk assessment; PERCUTANEOUS CORONARY INTERVENTION; SAPHENOUS-VEIN GRAFTS; BARE-METAL STENTS; OUTCOMES PRESTO TRIAL; OFF-LABEL USE; ANGIOGRAPHIC PREDICTORS; DIABETIC-PATIENTS; DECISION-MAKING; ARTERY-DISEASE; FOLLOW-UP;
D O I
10.1161/CIRCINTERVENTIONS.110.946939
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Prediction of restenosis after percutaneous coronary intervention (PCI) remains challenging, and existing risk assessment algorithms were developed before the widespread adoption of drug-eluting stents (DES). Methods and Results-We used data from the EVENT registry to develop a risk model for predicting target lesion revascularization (TLR) in 8829 unselected patients undergoing DES implantation between 2004 and 2007. Using a split-sample validation technique, predictors of TLR at 1 year were identified from two thirds of the subjects (derivation cohort) using multiple logistic regression. Integer point values were created for each predictor, and the summed risk score (range, 0 to 10) was applied to the remaining sample (validation cohort). At 1 year, TLR occurred in 4.2% of patients, and after excluding stent thrombosis and early mechanical complications, the incidence of late TLR (more likely representing restenosis-related TLR) was 3.6%. Predictors of TLR were age <60, prior PCI, unprotected left main PCI, saphenous vein graft PCI, minimum stent diameter <= 2.5 mm, and total stent length >= 40 mm. Comparison of observed versus predicted rates of TLR according to risk score demonstrated good model fit in the validation set. There was more than a 3-fold difference in TLR rates between the lowest risk category (score = 0; TLR rate, 2.2%) and the highest risk category (score >= 5; TLR rate, 7.5%). Conclusions-The overall incidence of TLR remains low among unselected patients receiving DES in routine clinical practice. A simple risk model incorporating 6 readily available clinical and angiographic variables helps identify individuals at extremely low (<2%) and modestly increased (>7%) risk of TLR after DES implantation. (Circ Cardiovasc Interv. 2010; 3: 327-334.)
引用
收藏
页码:327 / 334
页数:8
相关论文
共 36 条
[1]   The TIMI risk score for unstable angina/non-ST elevation MI - A method for prognostication and therapeutic decision making [J].
Antman, EM ;
Cohen, M ;
Bernink, PJLM ;
McCabe, CH ;
Horacek, T ;
Papuchis, G ;
Mautner, B ;
Corbalan, R ;
Radley, D ;
Braunwald, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (07) :835-842
[2]   Converting the Informed Consent From a Perfunctory Process to an Evidence-Based Foundation for Patient Decision Making [J].
Arnold, Suzanne V. ;
Decker, Carole ;
Ahmad, Homaa ;
Olabiyi, Olawale ;
Mundluru, Surya ;
Reid, Kimberly J. ;
Soto, Gabriel E. ;
Gansert, Sarah ;
Spertus, John A. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2008, 1 (01) :21-28
[3]  
Azzarelli S, 2008, J INVASIVE CARDIOL, V20, P62
[4]   Outcomes and complications associated with off-label and untested use of drug-eluting stents [J].
Beohar, Nirat ;
Davidson, Charles J. ;
Kip, Kevin E. ;
Goodreau, Lynne ;
Aslanidou Vlachos, Helen ;
Meyers, Sheridan N. ;
Benzuly, Keith H. ;
Flaherty, James D. ;
Ricciardi, Mark J. ;
Bennett, Charles L. ;
Williams, David O. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (18) :1992-2000
[5]   Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation results from an international trial of 9461 patients [J].
Boersma, E ;
Pieper, KS ;
Steyerberg, EW ;
Wilcox, RG ;
Chang, WC ;
Lee, KL ;
Akkerhuis, KM ;
Harrington, RA ;
Deckers, JW ;
Armstrong, PW ;
Lincoff, AM ;
Califf, RM ;
Topol, EJ ;
Simoons, ML .
CIRCULATION, 2000, 101 (22) :2557-2567
[6]   A Randomized Controlled Trial of a Paclitaxel-Eluting Stent Versus a Similar Bare-Metal Stent in Saphenous Vein Graft Lesions The SOS (Stenting Of Saphenous Vein Grafts) Trial [J].
Brilakis, Emmanouil S. ;
Lichtenwalter, Christopher ;
de Lemos, James A. ;
Roesle, Michele ;
Obel, Owen ;
Haagen, Donald ;
Saeed, Bilal ;
Gadiparthi, Chiranjeevi ;
Bissett, Joseph K. ;
Sachdeva, Rajesh ;
Voudris, Vassilios V. ;
Karyofillis, Panagiotis ;
Kar, Biswajit ;
Rossen, James ;
Fasseas, Panayotis ;
Berger, Peter ;
Banerjee, Subhash .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (11) :919-928
[7]   Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials [J].
Cutlip, DE ;
Chauhan, MS ;
Baim, DS ;
Ho, KKL ;
Popma, JJ ;
Carrozza, JP ;
Cohen, DJ ;
Kuntz, RE .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (12) :2082-2089
[8]   Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital registry [J].
Daemen, Jocst ;
Kukreja, Neville ;
van Twisk, Piet-Hein ;
Onuma, Yoshinobu ;
de Jaegere, Peter P. T. ;
van Domburg, Ron ;
Serruys, Patrick W. .
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (08) :1105-1111
[9]   Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes [J].
Hong, S. J. ;
Kim, M. H. ;
Ahn, T. H. ;
Ahn, Y. K. ;
Bae, J. H. ;
Shim, W. J. ;
Ro, Y. M. ;
Lim, D-S .
HEART, 2006, 92 (08) :1119-1124
[10]   Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era [J].
Jacob, S ;
Cohen, DJ ;
Massaro, J ;
Niemyski, P ;
Maresh, K ;
Kleiman, N .
AMERICAN HEART JOURNAL, 2005, 150 (05) :887-892